Selpercatinib

Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity[1][2].

Product Specifications

CAS Number

[2152628-33-4]

Product Name Alternative

LOXO-292

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

RET

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/RET_kinase_inhibitor_1.html

Purity

99.83

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

N#CC1=C2C(C3=CC=C(N4CC(C5)N(CC6=CC=C(OC)N=C6)C5C4)N=C3)=CC(OCC(C)(O)C)=CN2N=C1

Molecular Formula

C29H31N7O3

Molecular Weight

525.60

Precautions

H315, H319, H320

References & Citations

[1]Şentürk R, et, al. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jun 15;1147:122131.|[2]Steven W. Andrews, et al. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors. WO2018071447A1.